期刊
NATURE REVIEWS CARDIOLOGY
卷 15, 期 5, 页码 259-260出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrcardio.2018.38
关键词
-
资金
- NHLBI NIH HHS [R01 HL130020, F32 HL134221, R01 HL113006, R01 HL126527] Funding Source: Medline
Hyperlipidaemia is an important risk factor for coronary artery disease. Chadwick and colleagues report significantly reduced blood lipid levels following CRISPR-based in vivo genome editing in mice to introduce loss-of-function mutations in Angptl3, encoding a lipoprotein lipase inhibitor. Treatment was effective in both wild-type and Ldlr(-/-) mice and had a similar effect to that of Pcsk9-targeted genome editing, without causing off-target mutations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据